What does a talcum powder lead cost?

Raw leads cost $360-$470. Signed retainers cost approximately $940 via the Whitehardt benchmark. Some vendor sources report signed retainer costs of $2,600-$3,400 for premium qualified leads. The wide range reflects different qualification standards and vendor methodologies.

How many talcum powder lawsuits are pending?

Over 69,000 cases are pending in MDL-2738 in the District of New Jersey, making it the largest active MDL in the country. Case count grows by 400-500 new filings per month. Total filed cases exceed 75,000 across federal and state courts.

What are talcum powder settlements worth?

No global settlement has been reached. J&J's $9B offer was rejected in March 2025. Projected per-case values range from $100,000-$500,000 for ovarian cancer claims in a global settlement. Jury verdicts have been dramatically higher: $1.56B in Baltimore (Feb 2026), $966M in California (Oct 2025), and $2.12B in Missouri (2018).

Did J&J's bankruptcy strategy work?

No. J&J attempted the Texas Two-Step bankruptcy maneuver three times using subsidiaries LTL Management and Red River Talc LLC. All three were dismissed by courts. J&J is now fully exposed to jury trials with no bankruptcy shield.

Talcum Powder Lawsuit Advertising: 69,000 Cases, $1.56B Verdict, and J&J Has No Bankruptcy Shield | Mass Tort Report

$940 per signed retainer. Largest active MDL in the country. And the defendant just lost its third bankruptcy attempt.

Talcum powder is the tort that won’t die. Not because the science is new. The science has been building for 25 years. Because Johnson & Johnson keeps losing.

69,000 cases pending. $1.56 billion awarded in Baltimore last month. And the first federal bellwether trial is on the docket.

J&J Has No Shield

Johnson & Johnson tried three times to use the Texas Two-Step bankruptcy maneuver to contain talc liability. Three times the courts shut it down.

First attempt: LTL Management LLC in October 2021. Dismissed by the Third Circuit in January 2023. The subsidiary didn’t meet the “financial distress” requirement because J&J was funding it.

Second attempt: LTL again in April 2023 with an $8.9 billion offer over 25 years. Dismissed in July 2023. The Third Circuit ruled J&J couldn’t keep re-filing.

Third attempt: Red River Talc LLC in September 2024. New entity. New jurisdiction. $9 billion. The Texas bankruptcy judge rejected it in March 2025.

That’s it. No more shields. J&J faces jury trials in every jurisdiction with no bankruptcy firewall between the company and 69,000 cases.

The Verdicts

Juries don’t like Johnson & Johnson in talc cases. The numbers speak.

February 2026. Baltimore. A single mesothelioma plaintiff. $1.56 billion. The largest individual talc verdict in history.

October 2025. California. Another mesothelioma case. $966 million. Nearly a billion for one family.

The pattern is consistent. $40 million for two women with ovarian cancer in California (December 2025). $65.5 million for lung cancer in Minnesota. $20 million for mesothelioma in Florida. $42.6 million in Massachusetts.

The 2018 Missouri verdict: $4.69 billion for 22 women, reduced to $2.12 billion on appeal.

The gap between what J&J offers ($9 billion for 69,000+ cases, roughly $130,000 per claimant) and what juries award ($20 million to $1.56 billion) explains why plaintiffs keep rejecting settlements.

The MDL

MDL-2738 sits in the District of New Jersey under Judge Michael A. Shipp. The largest active MDL in the country. 69,000+ cases pending and growing by 400-500 per month.

January 2026 was the inflection point. Retired Judge Freda Wolfson released a 658-page recommendation clearing plaintiffs’ expert witnesses to testify on the talc-ovarian cancer link. J&J’s Daubert challenges failed.

That recommendation means the science goes to a jury. When the science goes to a jury, J&J loses more often than it wins.

First federal bellwether trial expected second half of 2026. State courts continue independently. The verdict pipeline isn’t slowing.

The Science

IARC upgraded talc to Group 2A in July 2024. “Probably carcinogenic to humans.” Up from Group 2B. That reclassification matters in court.

The research base is deep. Over 25 years of epidemiological data. The Nurses’ Health Study at Harvard found 20-30% increased ovarian cancer risk for regular perineal talc users. Multiple case-control studies confirmed the association.

The asbestos angle is devastating. Internal J&J documents from the 1960s and 1970s showed the company knew its talc products contained asbestos and made misleading statements claiming they didn’t. The FDA tested J&J Baby Powder in 2019 and found asbestos in samples. J&J pulled talc-based Baby Powder from the US market in 2020.

They knew. The documents are in evidence. Juries have read them. That’s why the verdicts keep climbing.

The Lead Economics

Talcum powder dropped from #1 to #7 on the Whitehardt Hot Tort Report. Score: 8.2. That drop represents declining ad spend, not declining case value.

The distinction matters. Advertising competition is down. Verdicts are up. The economics just improved for new entrants.

Whitehardt benchmarks: $470 per raw lead. $940 per signed retainer. Some vendor sources report $2,600-$3,400 for premium qualified leads with full medical documentation.

Projected settlement values: $100,000-$500,000 per ovarian cancer case in a global settlement. Jury verdict averages run $5 million to $40 million for ovarian cancer. Mesothelioma cases run $20 million and up.

The MOIC on a $940 CPA against a $300,000 mid-range settlement is 319:1. Even at the conservative floor, $100,000, that’s 106:1. Against the vendor cost ($3,400), the conservative MOIC is still 29:1.

Who’s Being Sued

Johnson & Johnson is the primary target. They manufactured Baby Powder and Shower to Shower. They inherited the liability and they can’t escape it.

The supplier chain adds defendants. Imerys Talc America filed Chapter 11 in February 2019 and established an $862 million asbestos trust with Cyprus Mines in February 2024. That trust pays mesothelioma claims from supplier-level exposure.

Colgate-Palmolive (Cashmere Bouquet), Avon Products, and other talc-containing cosmetic manufacturers are named in various cases. But J&J is the center of gravity.

The AG settlement of $700 million with 42 states covers consumer protection only. It doesn’t resolve individual injury claims.

The Advertising Playbook

Talcum powder is a mature tort with a traditional channel mix. TV still runs heavy.

Broadcast captures about 25% of spend. The plaintiff demographic is broader than most torts: women aged 45-75+ who used Baby Powder for decades. That demographic over-indexes on daytime and cable television.

Social runs strongest at 35%. Meta targeting for women with interest signals in health, wellness, and legal content. Lead gen forms with intake qualification built into the funnel.

Search takes 30%. “Talcum powder lawsuit” and “baby powder cancer” are competitive keyword spaces with high CPCs. The searchers already suspect a connection. Conversion rates are strong.

CTV is the open lane at 10%. The plaintiff demographic streams. They’re on Tubi, Peacock, and ad-supported cable replacements. Household-level targeting by age and health interest segments concentrates spend versus broadcast waste.

The Whitehardt drop from #1 to #7 means fewer firms competing for the same impressions. The firms that stayed in the market are acquiring at lower CPAs than 2023.

Qualification Criteria

Talcum powder has specific medical criteria. Ovarian, fallopian tube, or primary peritoneal cancer. Not uterine. Diagnosed within the last 10 years (2016 or later). Ages 18-70 at diagnosis.

Product use: minimum four years of perineal application before diagnosis. Adult use only. Childhood-only use doesn’t qualify.

No BRCA1 or BRCA2 genetic mutations. Not residing in Michigan or Texas. Not currently represented. Valid US SSN.

The strongest cases: long-duration perineal use (10+ years), serous or endometrioid ovarian cancer, no genetic risk factors, documented product purchase history. Those are the $300,000+ cases in a global settlement.

The Play

Talcum powder has the biggest inventory, the biggest verdicts, and declining advertising competition. Three things to watch.

First, the federal bellwether. When Judge Shipp sets the trial date for H2 2026, settlement pressure multiplies across the entire MDL. A plaintiff verdict in the largest active MDL creates shockwaves.

Second, the CPA window. Advertising dropped from #1 to #7 while verdicts climbed to $1.56 billion. That’s a buying opportunity. Firms acquiring now at $940 are entering a tort where juries have consistently valued cases at $5 million or more.

Third, no bankruptcy. J&J spent four years and three attempts trying to avoid jury trials. They failed. Every case in the MDL now has a path to trial.

The firms winning talcum powder aren’t waiting for J&J to propose another deal that plaintiffs reject. They’re building qualified case portfolios while the advertising market is soft and the verdict pipeline is hotter than it’s ever been.

References

Talcum powder is the largest active MDL in the country with 69,000+ cases, $940 CPAs, and projected settlements of $100K-$500K per ovarian cancer case. J&J's third bankruptcy attempt failed in March 2025. IARC upgraded talc to Group 2A in July 2024. Plaintiffs' experts cleared Daubert in January 2026. First federal bellwether trial expected H2 2026. Juries have awarded $1.56B (Baltimore), $966M (California), and $4.69B (Missouri) in individual and multi-plaintiff trials.